PL376302A1 - Nowe zastosowanie siarczanu dekstranu - Google Patents

Nowe zastosowanie siarczanu dekstranu

Info

Publication number
PL376302A1
PL376302A1 PL03376302A PL37630203A PL376302A1 PL 376302 A1 PL376302 A1 PL 376302A1 PL 03376302 A PL03376302 A PL 03376302A PL 37630203 A PL37630203 A PL 37630203A PL 376302 A1 PL376302 A1 PL 376302A1
Authority
PL
Poland
Prior art keywords
dextran sulfate
new use
human patient
cell transplant
therapeutic
Prior art date
Application number
PL03376302A
Other languages
English (en)
Other versions
PL216067B1 (pl
Inventor
Bo Nilsson
Olle Korsgren
Original Assignee
Prophymed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophymed Ab filed Critical Prophymed Ab
Publication of PL376302A1 publication Critical patent/PL376302A1/pl
Publication of PL216067B1 publication Critical patent/PL216067B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
PL376302A 2002-11-28 2003-11-26 Zastosowanie siarczanu dekstranu PL216067B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat

Publications (2)

Publication Number Publication Date
PL376302A1 true PL376302A1 (pl) 2005-12-27
PL216067B1 PL216067B1 (pl) 2014-02-28

Family

ID=20289705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376302A PL216067B1 (pl) 2002-11-28 2003-11-26 Zastosowanie siarczanu dekstranu

Country Status (25)

Country Link
US (5) US8629123B2 (pl)
EP (1) EP1567171B1 (pl)
JP (2) JP4315908B2 (pl)
KR (1) KR100828807B1 (pl)
CN (1) CN1296051C (pl)
AT (1) ATE359798T1 (pl)
AU (1) AU2003302378B2 (pl)
BR (1) BRPI0316666B8 (pl)
CA (1) CA2507595C (pl)
CY (1) CY1106739T1 (pl)
DE (1) DE60313356T2 (pl)
DK (1) DK1567171T3 (pl)
EA (1) EA010409B1 (pl)
ES (1) ES2285270T3 (pl)
HR (1) HRP20050439B1 (pl)
IL (1) IL168626A (pl)
IS (1) IS2405B (pl)
NO (1) NO326946B1 (pl)
NZ (1) NZ540744A (pl)
PL (1) PL216067B1 (pl)
PT (1) PT1567171E (pl)
SE (1) SE525461C3 (pl)
SI (1) SI1567171T1 (pl)
WO (1) WO2004047848A1 (pl)
ZA (1) ZA200504111B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007312880A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
US20110008343A1 (en) * 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
EP2550004A4 (en) * 2010-03-12 2014-07-02 Univ Australian HEPARANSULFATERSATZTHERAPIE
WO2012008908A1 (en) * 2010-07-16 2012-01-19 Tx Medic Ab Cell therapy
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
SE537742C2 (sv) 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
US10485817B2 (en) * 2014-06-12 2019-11-26 Tx Medic Ab Use of dextran sulfate having an average molecular weight below 10000 DA for inducing angiogenesis in a subject
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
EP3678675B1 (en) * 2017-09-08 2024-11-20 TX Medic AB New use of dextran sulfate
WO2021211043A1 (en) * 2020-04-15 2021-10-21 Tx Medic Ab Treatment of coronavirus infections
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases
SE544768C2 (en) * 2021-03-24 2022-11-08 Tx Medic Ab Combination for treatment of thromboinflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (pl) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CN1178070A (zh) * 1996-09-27 1998-04-08 刘春江 组织脏器移植用保存溶液·手术等时组织脏器保护溶液
CN1057192C (zh) * 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法

Also Published As

Publication number Publication date
EA200500757A1 (ru) 2005-12-29
US8906884B2 (en) 2014-12-09
CA2507595C (en) 2011-11-08
SE0203526L (sv) 2004-05-29
BRPI0316666B8 (pt) 2021-05-25
SI1567171T1 (sl) 2007-08-31
PL216067B1 (pl) 2014-02-28
ES2285270T3 (es) 2007-11-16
HK1087042A1 (en) 2006-10-06
US20140093484A1 (en) 2014-04-03
CA2507595A1 (en) 2004-06-10
HRP20050439A2 (en) 2005-12-31
DE60313356D1 (de) 2007-05-31
EP1567171A1 (en) 2005-08-31
AU2003302378B2 (en) 2008-02-21
CN1296051C (zh) 2007-01-24
NO326946B1 (no) 2009-03-16
US20140094435A1 (en) 2014-04-03
BRPI0316666B1 (pt) 2018-09-25
DK1567171T3 (da) 2007-07-16
EA010409B1 (ru) 2008-08-29
SE525461C2 (sv) 2005-02-22
WO2004047848A1 (en) 2004-06-10
NZ540744A (en) 2007-02-23
CY1106739T1 (el) 2012-05-23
US8629123B2 (en) 2014-01-14
US20160136331A1 (en) 2016-05-19
US9364499B2 (en) 2016-06-14
NO20052505L (no) 2005-06-20
ZA200504111B (en) 2006-07-26
JP2009167201A (ja) 2009-07-30
JP4315908B2 (ja) 2009-08-19
SE0203526D0 (sv) 2002-11-28
US20100113389A1 (en) 2010-05-06
HRP20050439B1 (hr) 2007-11-30
KR20050089803A (ko) 2005-09-08
IS2405B (is) 2008-09-15
ATE359798T1 (de) 2007-05-15
PT1567171E (pt) 2007-07-09
CN1717240A (zh) 2006-01-04
BR0316666A (pt) 2005-10-11
EP1567171B1 (en) 2007-04-18
US8901104B2 (en) 2014-12-02
US10307440B2 (en) 2019-06-04
JP2006509057A (ja) 2006-03-16
DE60313356T2 (de) 2007-08-16
AU2003302378A1 (en) 2004-06-18
US20060111319A1 (en) 2006-05-25
IL168626A (en) 2011-06-30
JP4972113B2 (ja) 2012-07-11
KR100828807B1 (ko) 2008-05-09
SE525461C3 (sv) 2005-03-23
IS7908A (is) 2005-06-23

Similar Documents

Publication Publication Date Title
SI1567171T1 (sl) Uporaba dekstran sulfata za zdravljenje IBMIR
EP2277992A3 (en) Progenitor cells from Wharton's jelly of human umbilical cord
AU7432796A (en) Retrievable bioartificial implants
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
WO2004009767A3 (en) Cell therapy for regeneration
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
AU2002239830A1 (en) Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
IT1307829B1 (it) Protesi dentale con mezzi per il rilascio di farmaci o fattorispecifici atti ad impedire l'insorgenza di infezioni e/o promuovere
EP2364708A3 (en) Pharmaceutical composition comprising a ClC-2 channel opener
DE60335202D1 (en) Chaperonin-10-immunosuppression
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
NZ533483A (en) Combinations of viscoelastics for use during surgery
IL131478A0 (en) Methods for treatment of scar tissue
WO1998024898A3 (en) Therapeutic composition comprising the kal protein and use of the kal protein
CA2473749A1 (en) Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof
GB9710698D0 (en) Composition
RU99111148A (ru) Глазные капли
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
ITTO20030126A1 (it) Composizione di integratore alimentare atta a favorire l'assorbimento del ferro.
PL356240A1 (pl) Stosowanie treosulfanu do dostosowania stanu pacjenta przed przeszczepem szpiku kości lub macierzystej komórki krwi
WO2002034283A3 (en) Vegh inhibitors and their use
MD1474F1 (en) Method of treatment of the puerperal endometritis